Now showing items 1897-1916 of 4635

    • Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro) 

      Robak, T; Matutes, E; Catovsky, D; Zinzani, PL; Buske, C; Comm, ESMOG (OXFORD UNIV PRESS, 2015-09)
    • Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation 

      Lo, ASY; Taylor, JR; Farzaneh, F; Kemeny, DM; Dibb, NJ; Maher, J (PERGAMON-ELSEVIER SCIENCE LTD, 2008-03)
      Aberrant growth factor production is a prevalent mechanism in tumourigenesis. If T-cells responded positively to a cancer-derived cytokine, this might result in selective enhancement of function within the tumour ...
    • Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. 

      Garrido, P; Adjei, AA; Bajpai, J; Banerjee, S; Berghoff, AS; Choo, SP; Felip, E; Furness, AJS; Garralda, E; Haanen, J; Letsch, A; Linardou, H; Peters, S; Sessa, C; Tabernero, J; Tsang, J; Yang, JC-H; Garassino, MC
      Background European Society for Medical Oncology Women for Oncology (ESMO W4O) research has previously shown under-representation of female oncologists in leadership roles. As early reports suggested disproportionate effects ...
    • Head and neck mucosal melanoma: The United Kingdom national guidelines. 

      Nenclares, P; Ap Dafydd, D; Bagwan, I; Begg, D; Kerawala, C; King, E; Lingley, K; Paleri, V; Paterson, G; Payne, M; Silva, P; Steven, N; Turnbull, N; Yip, K; Harrington, KJ
      The United Kingdom head and neck mucosal melanoma guideline development group used an evidence-based systematic approach to make recommendations in key areas of uncertainty in the field, including accurate diagnosis and ...
    • Health economic impact of liquid biopsies in cancer management. 

      IJzerman, MJ; Berghuis, AMS; de Bono, JS; Terstappen, LWMM (2018-12)
      Introduction Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly ...
    • Health-related quality of life among cancer patients in their last year of life: results from the PROFILES registry. 

      Raijmakers, NJH; Zijlstra, M; van Roij, J; Husson, O; Oerlemans, S; van de Poll-Franse, LV (2018-10)
      PURPOSE:The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS:Between 2008 and 2015, ...
    • Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. 

      Gounder, M; Abdul Razak, AR; Gilligan, AM; Leong, H; Ma, X; Somaiah, N; Chawla, SP; Martin-Broto, J; Grignani, G; Schuetze, SM; Vincenzi, B; Wagner, AJ; Chmielowski, B; Jones, RL; Shah, J; Shacham, S; Kauffman, M; Riedel, RF; Attia, S (2021-04-15)
      <b>Objective:</b> Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. <b>Materials & methods:</b> HRQoL was assessed at baseline and day 1 of each cycle ...
    • Health-related quality of life around the time of diagnosis in patients with bladder cancer. 

      Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; Bryan, RT; Wesselius, A; Zeegers, MP (2019-12)
      Objectives To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire QLQ-C30.Methods ...
    • Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK + non-small cell lung cancer (ALTA-1L). 

      Garcia Campelo, MR; Lin, HM; Zhu, Y; Pérol, M; Jahanzeb, M; Popat, S; Zhang, P; Camidge, DR
      Objective In ALTA-1 L, first-line brigatinib versus crizotinib significantly prolonged progression-free survival in advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). We report health-related quality of life ...
    • Health-related quality of life results from the phase III CheckMate 067 study. 

      Schadendorf, D; Larkin, J; Wolchok, J; Hodi, FS; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, J-J; Cowey, CL; Lao, C; Wagstaff, J; Callahan, MK; Postow, MA; Smylie, M; Ferrucci, PF; Dummer, R; Hill, A; Taylor, F; Sabater, J; Walker, D; Kotapati, S; Abernethy, A; Long, GV (2017-09)
      Background Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as ...
    • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 

      Brahmer, JR; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Zhang, J; Lubiniecki, GM; Deitz, AC; Rangwala, R; Reck, M (2017-12)
      Background In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer ...
    • HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients 

      Li, Z; Zhou, L; Prodromou, C; Savic, V; Pearl, LH (Elsevier BV, 2017-06)
    • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. 

      Qian, F; Wang, S; Mitchell, J; McGuffog, L; Barrowdale, D; Leslie, G; Oosterwijk, JC; Chung, WK; Evans, DG; Engel, C; Kast, K; Aalfs, CM; Adank, MA; Adlard, J; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Arun, BK; Ausems, MGEM; Azzollini, J; Barouk-Simonet, E; Barwell, J; Belotti, M; Benitez, J; Berger, A; Borg, A; Bradbury, AR; Brunet, J; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Caputo, SM; Chiquette, J; Claes, KBM; Margriet Collée, J; Couch, FJ; Coupier, I; Daly, MB; Davidson, R; Diez, O; Domchek, SM; Donaldson, A; Dorfling, CM; Eeles, R; Feliubadaló, L; Foretova, L; Fowler, J; Friedman, E; Frost, D; Ganz, PA; Garber, J; Garcia-Barberan, V; Glendon, G; Godwin, AK; Gómez Garcia, EB; Gronwald, J; Hahnen, E; Hamann, U; Henderson, A; Hendricks, CB; Hopper, JL; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, Á; Jakubowska, A; Kaczmarek, K; Kang, E; Karlan, BY; Kets, CM; Kim, S-W; Kim, Z; Kwong, A; Laitman, Y; Lasset, C; Hyuk Lee, M; Won Lee, J; Lee, J; Lester, J; Lesueur, F; Loud, JT; Lubinski, J; Mebirouk, N; Meijers-Heijboer, HEJ; Meindl, A; Miller, A; Montagna, M; Mooij, TM; Morrison, PJ; Mouret-Fourme, E; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nielsen, FC; Nussbaum, RL; Offit, K; Olah, E; Ong, K-R; Ottini, L; Park, SK; Peterlongo, P; Pfeiler, G; Phelan, CM; Poppe, B; Pradhan, N; Radice, P; Ramus, SJ; Rantala, J; Robson, M; Rodriguez, GC; Schmutzler, RK; Hutten Selkirk, CG; Shah, PD; Simard, J; Singer, CF; Sokolowska, J; Stoppa-Lyonnet, D; Sutter, C; Yen Tan, Y; Teixeira, RM; Teo, SH; Terry, MB; Thomassen, M; Tischkowitz, M; Toland, AE; Tucker, KM; Tung, N; van Asperen, CJ; van Engelen, K; van Rensburg, EJ; Wang-Gohrke, S; Wappenschmidt, B; Weitzel, JN; Yannoukakos, D; GEMO Study Collaborators; HEBON; EMBRACE; Greene, MH; Rookus, MA; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Goldgar, DE; Olopade, OI; Rebbeck, TR; Huo, D (2019-04)
      Background BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers remains ...
    • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. 

      Zhang, B; Shu, X-O; Delahanty, RJ; Zeng, C; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Wen, W; Long, J; Li, C; Dunning, AM; Chang-Claude, J; Shah, M; Perkins, BJ; Czene, K; Darabi, H; Eriksson, M; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Lambrechts, D; Neven, P; Wildiers, H; Floris, G; Schmidt, MK; Rookus, MA; van den Hurk, K; de Kort, WLAM; Couch, FJ; Olson, JE; Hallberg, E; Vachon, C; Rudolph, A; Seibold, P; Flesch-Janys, D; Peto, J; Dos-Santos-Silva, I; Fletcher, O; Johnson, N; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Li, J; Humphreys, K; Brand, J; Guénel, P; Truong, T; Cordina-Duverger, E; Menegaux, F; Burwinkel, B; Marme, F; Yang, R; Surowy, H; Benitez, J; Zamora, MP; Perez, JIA; Cox, A; Cross, SS; Reed, MWR; Andrulis, IL; Knight, JA; Glendon, G; Tchatchou, S; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Chenevix-Trench, G; kConFab Investigators, Australian Ovarian Study Group; Haiman, CA; Henderson, BE; Schumacher, F; Marchand, LL; Lindblom, A; Margolin, S; Hooning, MJ; Martens, JWM; Tilanus-Linthorst, MMA; Collée, JM; Hopper, JL; Southey, MC; Tsimiklis, H; Apicella, C; Slager, S; Toland, AE; Ambrosone, CB; Yannoukakos, D; Giles, GG; Milne, RL; McLean, C; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Swerdlow, AJ; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Garcia-Closas, M; Brinton, L; Lissowska, J; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Brüning, T; Ko, Y-D; Peterlongo, P; Manoukian, S; Bonanni, B; Radice, P; Bogdanova, N; Antonenkova, N; Dörk, T; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Devilee, P; Seynaeve, C; Van Asperen, CJ; Jakubowska, A; Lubiński, J; Jaworska-Bieniek, K; Durda, K; Hamann, U; Torres, D; Schmutzler, RK; Neuhausen, SL; Anton-Culver, H; Kristensen, VN; Grenaker Alnæs, GI; DRIVE Project; Pierce, BL; Kraft, P; Peters, U; Lindstrom, S; Seminara, D; Burgess, S; Ahsan, H; Whittemore, AS; John, EM; Gammon, MD; Malone, KE; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Baynes, C; Ahmed, S; Maranian, M; Healey, CS; González-Neira, A; Pita, G; Alonso, MR; Álvarez, N; Herrero, D; Pharoah, PDP; Simard, J; Hall, P; Hunter, DJ; Easton, DF; Zheng, W (2015-11)
      Background Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, the ...
    • Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. 

      Lophatananon, A; Stewart-Brown, S; Kote-Jarai, Z; Olama, AAA; Garcia, SB; Neal, DE; Hamdy, FC; Donovan, JL; Giles, GG; Fitzgerald, LM; Southey, MC; Pharoah, P; Pashayan, N; Gronberg, H; Wiklund, F; Aly, M; Stanford, JL; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Lin, H-Y; Sellers, T; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; APCB BioResource; PRACTICAL consortium; Easton, D; Eeles, RA; Muir, K (2017-08)
      Background Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods We analysed data ...
    • Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. 

      Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Widmark, A; Thuresson, M; Xu, L; Germino, J; Sartor, O (2017-02)
      Background Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding ...
    • Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model. 

      Andreou, T; Williams, J; Brownlie, RJ; Salmond, RJ; Watson, E; Shaw, G; Melcher, A; Wurdak, H; Short, SC; Lorger, M
      Patients with glioblastoma (GBM) have a poor prognosis, and inefficient delivery of drugs to tumors represents a major therapeutic hurdle. Hematopoietic stem cell (HSC)-derived myeloid cells efficiently home to GBM and ...